International Symposium Will Address Non-Hodgkins Lymphoma in the Young
World-renowned Non-Hodgkins Lymphoma researchers and clinicians will explore latest discoveries and treatments, Nov. 1-3
Valhalla, NY, Oct. 29, 2012 - Fifty world-renowned experts in non-Hodgkins lymphoma will convene in New York in November to present the latest scientific and clinical advances in treating a “lost generation” of sufferers—children, young adults and adolescents.
The Fourth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkins Lymphoma is scheduled for November 1-3, 2012, at the Sheraton New York Hotel and Towers in New York City.
The symposium, which is offered once every three years, is coordinated by researchers and clinicians at New York Medical College, Westchester Medical Center and its Maria Fareri Children’s Hospital, all in Valhalla, New York; Justus-Liebig University, Children’s University Hospital in Giessen, Germany, and the Pediatric Cancer Research Foundation in Irvine, California.
Organizers say it is the only international, national or regional conference dedicated to the study of non-Hodgkins lymphoma in children, adolescents and young adults.
“This symposium attracts more than 300 of the world’s most prominent experts in the field of pediatric oncology,” explained Mitchell Cairo, M.D., of New York Medical College and Maria Fareri Children’s Hospital at Westchester Medical Center, a lead organizer of the event along with Alfred Reiter, M.D., of Justus-Liebig University. Presenters hail from the most prestigious medical, academic and scientific institutions in the world and will gather with attendees from 40 countries on 6 continents to explore and discuss the latest advances in the basic, clinical and translational sciences.
“Lymphoma is the third most common cancer in children under 15 years of age and the most common cancer in adolescents and young adults age 15-35, accounting for one out of every four cancers in that age group. It is our deepest hope and intention that research presented and discussed at the symposium will aid in the care of children suffering from lymphomas and other types of cancers,” said Dr. Cairo.
Workshops, oral and poster presentations, plenary sessions and special seminars will address the latest discoveries in genomics, proteomics, immunology, tumor immunology, stem cell transplantation and immunology, and targeted therapeutics in childhood, adolescent and young adult hematological malignancies.
Highlights include a Rare Pediatric Non-Hodgkin’s Lymphoma Workshop and sessions on Novel Therapeutics, Lymphoblastic Lymphoma and a special meeting between the lecturers and conference participants.
Abstracts will be published in the November British Journal of Hematology.
To register, or to access the complete program and additional information, go to http://bit.ly/PtY54V_NHL-Symp.
Donna Moriarty, MPH
For Additional Information:
New York Medical College, a member of the Touro College and University System, is one of the nation’s largest private health sciences universities with more than 1,400 students and 850 residents and fellows and nearly 3,000 faculty members. The leading academic biomedical research institution between New York City and Albany, the university manages more than $34 million in research and other sponsored programs, notably in the areas of cardiovascular disease, cancer, kidney disease, the neurosciences and infectious diseases. www.nymc.edu
Maria Fareri Children’s Hospital at Westchester Medical Center is the children’s hospital for New York’s Hudson Valley region and Fairfield County, Connecticut. As home to the area’s only pediatric intensive care unit, pediatric transplant program, burn center, cardiac catheterization program and its regional neonatal intensive care unit, Maria Fareri Children’s Hospital cares for the area’s most seriously ill and injured kids.
The Pediatric Cancer Research Foundation (PCRF) has been funding lead pediatric cancer researchers since its founding in 1982. Dedicated to its mission to “improve the care, quality of life, and survival rates of children with malignant diseases,” PCRF has raised almost $30 million to support the continual advancement of cutting edge research, education and lifesaving treatments for children with cancer. www.pcrf-kids.org